Tuesday, September 05, 2023
ACM Biolabs has announced positive top-line findings from the Phase I trial of ACM-001, marking a significant milestone in their first clinical-stage development programme.
ACM-001 is a booster vaccine designed to enhance immunity against SARS-CoV-2, the causative agent of COVID-19. It consists of a spike-protein component sourced from the immune-evasive beta SARS-CoV-2 variant and an immunostimulant called CpG 7909, which is delivered using a polymer-based delivery technology.
This Phase I trial was conducted with the participation of thirty-six subjects at six different sites across Australia. The results demonstrate that ACM-001 was well-received and exhibited a high level of safety and tolerance when administered through both standard intramuscular injection and mucosal delivery routes.
The initial data related to immunogenicity is particularly promising. The intramuscular administration of the vaccine appears to have triggered a robust antibody response with broad reactivity. This immune response targets not only previous variants of the virus but also the presently circulating omicron strains, offering hope for effective protection against current and emerging forms of the virus.
